Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma

In brief

RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of a chemotherapy drug by making cancer cells more sensitive to the drug. Combining oblimersen with rituximab and combination chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of oblimersen when given together with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in treating patients with stage II, stage III, or stage IV large B-cell lymphoma

Key facts

Study ID

NCT00070083

Run by

British Columbia Cancer Agency

Starts

2003-07-01

Last updated by the study team

2009-04-07

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford Cancer Center at Stanford University Medical Center — Stanford, California, United States
• British Columbia Cancer Agency - Centre for the Southern Interior — Kelowna, British Columbia, Canada
• Fraser Valley Cancer Centre at British Columbia Cancer Agency — Surrey, British Columbia, Canada
• British Columbia Cancer Agency - Vancouver Cancer Centre — Vancouver, British Columbia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.